Answers are grounded in this paper and cite their sources.
Clinical trial demonstrates a 40% objective tumor response from erdafitinib in advanced FGFR-altered urothelial carcinoma, highlighting its therapeutic potential despite frequent adverse events.
The use of erdafitinib was associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations. Treatment-related grade 3 or higher adverse events were reported in nearly half the patients. (Funded by Janssen Research and Development; BLC2001 ClinicalTrials.gov number, NCT02365597.).
No takes yet. Share an insight, caveat, or question.
Loriot et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: